Phase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer. (Q33408000)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Phase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23712440%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Phase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23712440%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23712440%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23712440%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

author name string

Changhoon Yoo

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23712440%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Min-Hee Ryu

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23712440%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Young-Soon Na

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23712440%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Baek-Yeol Ryoo

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23712440%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Chae-Won Lee

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23712440%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Jeheon Maeng

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23712440%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Se-Yeon Kim

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23712440%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Yoon-Koo Kang

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23712440%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

publication date

28 May 2013

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23712440%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23712440%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

32

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23712440%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23712440%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

271-278

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23712440%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9983-2

21 January 2018

Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9983-2

21 January 2018

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9983-2

21 January 2018

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9983-2

21 January 2018

Anticancer activities of histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9983-2

21 January 2018

FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9983-2

21 January 2018

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9983-2

21 January 2018

A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9983-2

21 January 2018

A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9983-2

21 January 2018

Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9983-2

21 January 2018

Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9983-2

21 January 2018

The global histone modification pattern correlates with cancer recurrence and overall survival in gastric adenocarcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9983-2

21 January 2018

Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9983-2

21 January 2018

Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9983-2

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9983-2

21 January 2018

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9983-2

21 January 2018

Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9983-2

21 January 2018

Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9983-2

21 January 2018

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9983-2

21 January 2018

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9983-2

21 January 2018

Histone deacetylase inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/23712440

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-013-9983-2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23712440%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23712440%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33408000&oldid=2195332168"